Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Adolescent
Antiemetics
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Child
Child, Preschool
Female
Granisetron
/ administration & dosage
Hematologic Neoplasms
/ drug therapy
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Infant
Male
Morpholines
/ administration & dosage
Nausea
/ chemically induced
Transplantation Conditioning
/ adverse effects
Vomiting
/ chemically induced
Antiemetic prophylaxis
Chemotherapy-induced nausea and vomiting
Fosaprepitant
Granisetron
Hematopoietic stem cell transplantation
Pediatric
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
24
09
2019
accepted:
30
01
2020
pubmed:
15
2
2020
medline:
4
4
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
Chemotherapy-induced nausea and vomiting (CINV) is a severe and distressing complication during allogeneic hematopoietic stem cell transplantation (alloHSCT). The antiemetic fosaprepitant has shown favorable results in pediatric and adult patients receiving chemotherapy. Data on fosaprepitant in children and adolescents undergoing alloHSCT are missing. In this non-interventional observation study, 120 children and adolescents with a median age of 11.8 years undergoing alloHSCT after a moderately or highly emetogenic conditioning (MEC or HEC) were analyzed. They received an antiemetic prophylaxis with granisetron (2 × 40 µg/kg d During MEC, significantly more patients in the CG experienced vomiting during the first 0-24 h (58.6 vs. 25.0%; p = 0.0156) and during > 24-120 h (93.1% vs. 57.1%; p = 0.0020), compared with the FG. Likewise, significantly more vomiting events (269 vs. 136; p < 0.0001) were registered in the CG. During HEC, significantly more patients in the CG experienced vomiting during the first 0-24 h (32.3 vs. 9.4%; p = 0.0319) compared with the FG. Significantly more vomiting events (241 vs. 99; p < 0.0001) were registered in the CG. Laboratory and clinical adverse events were not significantly different between the two groups (p > 0.05). Antiemetic prophylaxis with fosaprepitant and granisetron was well tolerated, safe, and effective in pediatric patients undergoing alloHSCT. However, larger prospective trials are necessary to evaluate these findings.
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy-induced nausea and vomiting (CINV) is a severe and distressing complication during allogeneic hematopoietic stem cell transplantation (alloHSCT). The antiemetic fosaprepitant has shown favorable results in pediatric and adult patients receiving chemotherapy. Data on fosaprepitant in children and adolescents undergoing alloHSCT are missing.
METHODS
METHODS
In this non-interventional observation study, 120 children and adolescents with a median age of 11.8 years undergoing alloHSCT after a moderately or highly emetogenic conditioning (MEC or HEC) were analyzed. They received an antiemetic prophylaxis with granisetron (2 × 40 µg/kg d
RESULTS
RESULTS
During MEC, significantly more patients in the CG experienced vomiting during the first 0-24 h (58.6 vs. 25.0%; p = 0.0156) and during > 24-120 h (93.1% vs. 57.1%; p = 0.0020), compared with the FG. Likewise, significantly more vomiting events (269 vs. 136; p < 0.0001) were registered in the CG. During HEC, significantly more patients in the CG experienced vomiting during the first 0-24 h (32.3 vs. 9.4%; p = 0.0319) compared with the FG. Significantly more vomiting events (241 vs. 99; p < 0.0001) were registered in the CG. Laboratory and clinical adverse events were not significantly different between the two groups (p > 0.05).
CONCLUSIONS
CONCLUSIONS
Antiemetic prophylaxis with fosaprepitant and granisetron was well tolerated, safe, and effective in pediatric patients undergoing alloHSCT. However, larger prospective trials are necessary to evaluate these findings.
Identifiants
pubmed: 32056007
doi: 10.1007/s00432-020-03143-8
pii: 10.1007/s00432-020-03143-8
pmc: PMC7085480
doi:
Substances chimiques
Antiemetics
0
Morpholines
0
fosaprepitant
6L8OF9XRDC
Granisetron
WZG3J2MCOL
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1089-1100Subventions
Organisme : Stefan-Morsch-Stiftung, Birkenfeld, Germany
ID : -
Références
Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20:450–458. https://doi.org/10.1634/theoncologist.2014-0229
doi: 10.1634/theoncologist.2014-0229
pubmed: 25795636
pmcid: 4391760
Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K, LaPointe J, Liu Q, Hsieh CC, Hesketh PJ (2001) Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 28:1061–1066. https://doi.org/10.1038/sj.bmt.1703280
doi: 10.1038/sj.bmt.1703280
pubmed: 11781617
Celio L, Ricchini F, De Braud F (2013) Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence 7:391–400. https://doi.org/10.2147/ppa.s31288
doi: 10.2147/ppa.s31288
pubmed: 23687442
pmcid: 3653760
Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24:2065–2071. https://doi.org/10.1016/j.bbmt.2018.06.005
doi: 10.1016/j.bbmt.2018.06.005
pubmed: 29906570
Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P, Holdsworth M (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57:191–198. https://doi.org/10.1002/pbc.23114
doi: 10.1002/pbc.23114
pubmed: 21465637
Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, O'Shaughnessy E, Sung L (2013) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 60:1073–1082. https://doi.org/10.1002/pbc.24508
doi: 10.1002/pbc.24508
pubmed: 23512831
Dupuis LL, Sung L, Molassiotis A, Orsey AD, Tissing W, van de Wetering M (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25:323–331. https://doi.org/10.1007/s00520-016-3384-y
doi: 10.1007/s00520-016-3384-y
pubmed: 27565788
Duquette D, Adam JP, Goulet D, Delage R (2011) Retrospective analysis of the efficacy of antiemetic prophylaxis in different preparative regimens for autologous and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 17:S282. https://doi.org/10.1016/j.bbmt.2010.12.389
doi: 10.1016/j.bbmt.2010.12.389
Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308. https://doi.org/10.1007/s00520-016-3449-y
doi: 10.1007/s00520-016-3449-y
pubmed: 27815710
European Medicines Agency (EMA)—Committee for Medicinal Products for Human Use (CHMP) (2018) Assessment report Ivemend—Procedure No. EMEA/H/C/000743/II/0037. https://www.ema.europa.eu/documents/variation-report/ivemend-h-c-743-ii-0037-epar-assessment-report-variation_en.pdf . Accessed 12 Dec 2018
Flank J, Sparavalo J, Vol H, Hagen L, Stuhler R, Chong D, Courtney S, Doyle JJ, Gassas A, Schechter T, Dupuis LL (2017) The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study. Bone Marrow Transplant 52:1294–1299. https://doi.org/10.1038/bmt.2017.112
doi: 10.1038/bmt.2017.112
pubmed: 28581463
Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol 29:1495–1501. https://doi.org/10.1200/jco.2010.31.7859
doi: 10.1200/jco.2010.31.7859
pubmed: 21383291
Kusnierczyk NM, Saunders EF, Dupuis LL (2002) Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 30:119–124. https://doi.org/10.1038/sj.bmt.1703579
doi: 10.1038/sj.bmt.1703579
pubmed: 12132051
McKenzie E, Zaki P, Raman S, Olson R, McFarlane T, DeAngelis C, Chan S, Pidduck W, Razvi Y, Bushehri A, Chow E (2019) Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer 27:783–791. https://doi.org/10.1007/s00520-018-4586-2
doi: 10.1007/s00520-018-4586-2
pubmed: 30607675
Patel P, Leeder JS, Piquette-Miller M, Dupuis LL (2017a) Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.13322
doi: 10.1111/bcp.13322
pubmed: 28833380
pmcid: 5736843
Patel P, Robinson PD, Thackray J, Flank J, Holdsworth MT, Gibson P, Orsey A, Portwine C, Freedman J, Madden JR, Phillips R, Sung L, Dupuis LL (2017b) Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26542
doi: 10.1002/pbc.26542
pubmed: 28853209
Radhakrishnan V, Joshi A, Ramamoorthy J, Rajaraman S, Ganesan P, Ganesan TS, Dhanushkodi M, Sagar TG (2018) Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.27551
doi: 10.1002/pbc.27551
pubmed: 30426714
Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2013) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24:1067–1073. https://doi.org/10.1093/annonc/mds541
doi: 10.1093/annonc/mds541
pubmed: 23117073
Saito Y, Kumamoto T, Arima T, Shirakawa N, Ishimaru S, Sonoda T, Nakajima M, Sugiyama M, Arakawa A, Hashimoto H, Makino Y, Ogawa C, Yamaguchi M (2019) Evaluation of aprepitant and fosaprepitant in pediatric patients. Pediatr int. https://doi.org/10.1111/ped.13780
doi: 10.1111/ped.13780
pubmed: 31612604
Shillingburg A, Biondo L (2014) Aprepitant and fosaprepitant use in children and adolescents at an academic medical center. J Pediatr Pharmacol Ther 19:127–131. https://doi.org/10.5863/1551-6776-19.2.127
doi: 10.5863/1551-6776-19.2.127
pubmed: 25024673
pmcid: 4093665
Timaeus S, Elder J, Franco K (2018) Evaluation of the use of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients. J Pediatr Hematol Oncol 40:527–531. https://doi.org/10.1097/mph.0000000000001213
doi: 10.1097/mph.0000000000001213
pubmed: 29794645
U.S. NIH-NCI (2010) Common Terminology Criteria for Adverse Events v4.03 (CTCAE) 2010. U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute
US Food and Drug Administration (2018) EMEND—Fosaprepitant Dimeglumine. NDA 022023—SUPPL-17. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM605696.pdf . Accessed 12 Dec 2018